Browsing by author "Garcia-Murillas, Isaac"
Now showing items 1-20 of 29
-
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
Schiavon, G; Hrebien, S; Garcia-Murillas, I; Cutts, RJ; Pearson, A; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2015-11-11)Acquired ESR1 mutations are a major mechanism of resistance to aromatase inhibitors (AIs). We developed ultra high-sensitivity multiplex digital polymerase chain reaction assays for ESR1 mutations in circulating tumor DNA ... -
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
Fitzpatrick, A; Iravani, M; Mills, A; Childs, L; Alaguthurai, T; et al. (AMER ASSOC CANCER RESEARCH, 2022-03-15)PURPOSE: Cerebrospinal fluid (CSF) cytology is the gold standard diagnostic test for breast cancer leptomeningeal metastasis (BCLM), but has impaired sensitivity, often necessitating repeated lumbar puncture to confirm or ... -
Assessing HER2 Amplification in Plasma cfDNA.
Garcia-Murillas, I; Turner, NC (HUMANA PRESS INC, 2018-05-02)Digital PCR (dPCR) is a highly accurate method to determine DNA concentration. In dPCR, DNA is portioned into many discrete single entities, and these are analyzed individually for the presence or absence of a target ... -
Assessment of molecular relapse detection in early-stage breast cancer
Garcia-Murillas, I; Chopra, N; Comino-Mendez, I; Beany, M; Tovey, H; et al. -
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Pascual, J; Gil-Gil, M; Proszek, P; Zielinski, C; Reay, A; et al. (AMER ASSOC CANCER RESEARCH, 2023-10-13)PURPOSE: Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early ... -
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
O'Leary, B; Cutts, RJ; Huang, X; Hrebien, S; Liu, Y; et al. (OXFORD UNIV PRESS INC, 2021-03-01)BACKGROUND: There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor ... -
Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
Allin, DM; Shaikh, R; Carter, P; Thway, K; Sharabiani, MTA; et al. (ELSEVIER SCI LTD, 2018-11-01)BACKGROUND: Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in ... -
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
O'Leary, B; Hrebien, S; Beaney, M; Fribbens, C; Garcia-Murillas, I; et al. (AMER ASSOC CLINICAL CHEMISTRY, 2019-11-01)BACKGROUND: Circulating tumor DNA (ctDNA) assays are increasingly used for clinical decision-making, but it is unknown how well different assays agree. We aimed to assess the agreement in ctDNA mutation calling between ... -
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Coakley, M; Villacampa, G; Sritharan, P; Swift, C; Dunne, K; et al. (AMER ASSOC CANCER RESEARCH, 2024-02-16)PURPOSE: Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk of relapse, yet the optimal assay for ctDNA detection is unknown. ... -
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin, L-A; Ribas, R; Simigdala, N; Schuster, E; Pancholi, S; et al. (NATURE PORTFOLIO, 2017-11-30)Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, ... -
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
O'Leary, B; Hrebien, S; Morden, JP; Beaney, M; Fribbens, C; et al. (NATURE PORTFOLIO, 2018-03-01)CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA ... -
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Hrebien, S; Citi, V; Garcia-Murillas, I; Cutts, R; Fenwick, K; et al. (ELSEVIER, 2019-06-01)BACKGROUND: Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression-free ... -
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; et al. (PUBLIC LIBRARY SCIENCE, 2015-09-28)Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ... -
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.
Turner, NC; Swift, C; Kilburn, L; Fribbens, C; Beaney, M; et al. (AMER ASSOC CANCER RESEARCH, 2020-10-01)PURPOSE: ESR1 mutations are acquired frequently in hormone receptor-positive metastatic breast cancer after prior aromatase inhibitors. We assessed the clinical utility of baseline ESR1 circulating tumor DNA (ctDNA) analysis ... -
Genomic profile of advanced breast cancer in circulating tumour DNA.
Kingston, B; Cutts, RJ; Bye, H; Beaney, M; Walsh-Crestani, G; et al. (NATURE PORTFOLIO, 2021-04-23)The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating ... -
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, MK; et al. (AMER ASSOC CANCER RESEARCH, 2020-02-01)PURPOSE: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential ... -
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Dréan, A; Williamson, CT; Brough, R; Brandsma, I; Menon, M; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Although PARP inhibitors target BRCA1- or BRCA2-mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or "revertant" mutations in BRCA1 or BRCA2 ... -
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Lopez-Knowles, E; Pearson, A; Schuster, G; Gellert, P; Ribas, R; et al. (SPRINGERNATURE, 2019-01-22)BACKGROUND: Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS ... -
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors.
Coakley, M; Garcia-Murillas, I; Turner, NC (AMER ASSOC CANCER RESEARCH, 2019-10)Advances in diagnosis and treatment have resulted in a high rate of survival for many patients with early-stage cancers. However, identifying who is at ongoing risk of relapse remains of high priority to direct subsequent ... -
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
Garcia-Murillas, I; Schiavon, G; Weigelt, B; Ng, C; Hrebien, S; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2015-08-26)The identification of early-stage breast cancer patients at high risk of relapse would allow tailoring of adjuvant therapy approaches. We assessed whether analysis of circulating tumor DNA (ctDNA) in plasma can be used to ...